TABLE 2 .
Relationship between clonal complex, NHBA peptide, and MATS-predicted coverage for 105 disease-associated serogroup B isolates
| NHBA peptide |
Predicted coverage from MATS-NHBA relative potency valuesa |
% NHBA peptide prevalence |
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cc41/44 (n = 45) |
cc269 (n = 23) |
cc213 (n = 5) |
cc32 (n = 5) |
cc162 (n = 4) |
cc35 (n = 2) |
Others |
Overall (n = 105) |
||||||||||
| Total | Cov. | Total | Cov. | Total | Cov. | Total | Cov. | Total | Cov. | Total | Cov. | Total | Cov. | Total | Cov. | ||
| 2 | 31 | 30 (97) | 31 | 30 (97) | 29.5 | ||||||||||||
| 21 | 14 | 7 (50) | 2 | 0 | 1 | 0 | 17 | 7 (41) | 16.2 | ||||||||
| 17 | 7 | 0 | 4 | 0 | 11 | 0 | 10.5 | ||||||||||
| 20 | 1 | 0 | 4 | 1 (25) | 6 | 1 (17) | 11 | 2 (18) | 10.5 | ||||||||
| 18 | 4 | 0 | 4 | 0 | 3.8 | ||||||||||||
| 24 | 1 | 0 | 3 | 0 | 4 | 0 | 3.8 | ||||||||||
| 607 | 5 | 4 (80) | 5 | 4 (80) | 4.8 | ||||||||||||
| Others | 8 | 2 (25) | 2 | 0 | 1 | 0 | 4 | 2 (50) | 7 | 0 | 22 | 4 (18) | 21 | ||||
a
Total, total number of isolates tested; Cov., total number (percent) of isolates covered.